Vericel (NASDAQ:VCEL – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Risk and Volatility
Vericel has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.
Insider and Institutional Ownership
75.4% of Janux Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Vericel and Janux Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $324.17 million | 9.05 | $16.52 million | $0.64 | 89.88 |
| Janux Therapeutics | $23.29 million | 26.48 | -$113.62 million | ($1.59) | -6.34 |
Vericel has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Vericel and Janux Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 10.27% | 9.09% | 6.68% |
| Janux Therapeutics | N/A | -11.80% | -10.97% |
Analyst Recommendations
This is a summary of current ratings and target prices for Vericel and Janux Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 2 | 5 | 1 | 2.88 |
| Janux Therapeutics | 2 | 3 | 10 | 1 | 2.62 |
Vericel currently has a consensus target price of $62.00, suggesting a potential upside of 7.79%. Janux Therapeutics has a consensus target price of $36.92, suggesting a potential upside of 266.30%. Given Janux Therapeutics’ higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Vericel.
Summary
Vericel beats Janux Therapeutics on 8 of the 14 factors compared between the two stocks.
About Vericel
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
About Janux Therapeutics
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
